Search results for " Embolism"

showing 10 items of 311 documents

Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation

2013

Background Scores for cardio-embolic and bleeding risk in patients with atrial fibrillation are described in the literature. However, it is not clear how they co-classify elderly patients with multimorbidity, nor whether and how they affect the physician's decision on thromboprophylaxis. Methods Four scores for cardio-embolic and bleeding risks were retrospectively calculated for ≥ 65 year old patients with atrial fibrillation enrolled in the REPOSI registry. The co-classification of patients according to risk categories based on different score combinations was described and the relationship between risk categories tested. The association between the antithrombotic therapy received and t…

RegistrieMaleEmbolismAtrial fibrillation; Bleeding risk; Cardioembolic risk; Elderly; Prediction guides; Thromboprophylaxis; Aged; Aged; 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Female; Hemorrhage; Humans; Logistic Models; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Warfarin; Registries; Risk Assessment; Internal MedicineRetrospective Studiearitmiableeding risk scoreAtrial Fibrillation80 and overatrial fibrillationRegistriesStrokeAged 80 and overAspirineducation.field_of_studyElderly Atrial fibrillation Prediction guides Bleeding risk Cardioembolic risk ThromboprophylaxisPrediction guidesAtrial fibrillationCardiovascular diseaseStrokecardio-embolic scorePlatelet aggregation inhibitorcardio-embolic scores; bleeding risk scores; elderly; Atrial FibrillationFemaleRisk assessmentmedicine.drugHumanmedicine.medical_specialtyLogistic Modelcardio-embolic scoresPopulationHemorrhageRisk AssessmentelderlyCARDIOEMBOLIC RISKNOBLEEDING RISKInternal medicinemedicineElderly; Atrial fibrillation; Prediction guides; Bleeding risk; Cardioembolic riskbleeding risk scoresPrediction guideInternal MedicineHumanseducationThromboprophylaxisAgedRetrospective StudiesELDERLYbusiness.industryPlatelet Aggregation InhibitorSettore MED/09 - MEDICINA INTERNAWarfarinAnticoagulantAnticoagulantsRetrospective cohort studyAtrial fibrillation; Bleeding risk; Cardioembolic risk; Elderly; Prediction guides; Thromboprophylaxis; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Female; Hemorrhage; Humans; Logistic Models; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Warfarin; Registries; Risk Assessment; Internal Medicinemedicine.diseaseSurgeryLogistic ModelsThromboprophylaxiWarfarinbusinessPlatelet Aggregation Inhibitors
researchProduct

When sepsis affects the heart: A case report and literature review

2015

A 59-year-old nursing home patient with Down syndrome was brought to the internal medicine department of our hospital due to fever, cough without expectorate, and dyspnea. A thoracic computed tomography revealed the presence of bilateral basal parenchymal opacities. Her condition deteriorated after admission and troponin reached a peak serum concentration of 16.9 ng/mL. The patient was in cardiogenic shock. In addition to fluid resuscitation, vaso-active amine infusion was administered to achieve hemodynamic stabilization. The differential diagnosis investigated possible pulmonary embolism, myocardial infarction, and myocarditis. Furthermore, a second transthoracic echocardiogram suggested …

Resuscitationmedicine.medical_specialtyMyocarditisbusiness.industryCardiogenic shockCase ReportGeneral Medicinemedicine.diseasePulmonary embolismSurgerySepsisInternal medicineShock (circulatory)medicineCardiologyMyocardial infarctionmedicine.symptomTransthoracic echocardiogrambusiness
researchProduct

The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes

2015

Background. Critically ill patients appear to be at high risk of developing deep vein thrombosis (DVT) and pulmonary embolism during their stay in the intensive care unit (ICU). However, little is known about the clinical course of venous thromboembolism in the ICU setting. We therefore evaluated, through a systematic review of the literature, the available data on the impact of a diagnosis of DVT on hospital and ICU stay, duration of mechanical ventilation and mortality in critically ill patients. We also tried to determine whether currently adopted prophylactic measures need to be revised and improved in the ICU setting. Materials and methods. MEDLINE and EMBASE databases were searched up…

RiskCritical IllnessIntensive Care UnitCritically ill patients; Deep vein thrombosis; Meta-analysis; Outcomes; Cohort Studies; Hospital Mortality; Humans; Intensive Care Units; Length of Stay; Pulmonary Embolism; Randomized Controlled Trials as Topic; Research Design; Respiration Artificial; Risk; Thrombophilia; Treatment Outcome; Venous Thrombosis; Critical Illness; Hematology; Immunology and AllergyReviewDeep Vein Thrombosis Critically Ill Patients outcomes metanalysisCohort StudiesDeep vein thrombosiImmunology and AllergyHumansThrombophiliaMeta-analysiVenous ThrombosiHospital MortalityOutcomeRandomized Controlled Trials as TopicVenous ThrombosisHematologyLength of StayRespiration ArtificialIntensive Care UnitsTreatment OutcomeResearch DesignCritical IllneCritically ill patientCohort StudiePulmonary EmbolismHuman
researchProduct

Ambulatory treatment of low-risk pulmonary embolism in fragile patients: a subgroup analysis of the multinational Home Treatment of Pulmonary Embolis…

2020

Pulmonary embolism is the third most frequent acute cardiovascular disease with an annual incidence of approximately 100 cases per 100 000 population and an annual mortality of ≥7 deaths per 100 000 population in the European region [1, 2]. Initial management is adjusted to the risk of in-hospital death or early complications, which depend both on the severity of pulmonary embolism and the presence of comorbidities [3]. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors hav…

RiskPulmonary and Respiratory Medicinemedicine.medical_specialtyDownloadPopulationMEDLINESubgroup analysisGerman03 medical and health sciences0302 clinical medicineHealth careAmbulatory CaremedicineHumans030212 general & internal medicineeducationeducation.field_of_studybusiness.industryConflict of interestlanguage.human_language030228 respiratory systemMultinational corporationFamily medicinelanguagePulmonary EmbolismbusinessEuropean Respiratory Journal
researchProduct

Optimizing the Personalized, Risk-Adjusted Management of Pulmonary Embolism: An Integrated Clinical Trial Programme

2018

Acute pulmonary embolism (PE) contributes significantly to the global burden of cardiovascular disease. The severity of the acute PE event determines the expected estimated risk of early death. This risk is influenced by the degree of dysfunction of the right ventricle (RV), as assessed by the presence of acute RV pressure overload on imaging and/or elevated cardiac biomarkers, and by demographic and clinical factors, including relevant comorbidities. Haemodynamic instability and cardiogenic shock is at the top of the PE severity spectrum, as it represents the most extreme manifestation of RV failure and a key determinant of poor prognosis. Ideally, risk-adjusted treatment should implement:…

Riskmedicine.medical_specialtyAcademic clinical trialCost-Benefit AnalysisDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineReperfusion therapymedicineHumansPrecision MedicineClinical Trials as Topicbusiness.industryCardiogenic shockHematologymedicine.diseaseThrombosisPulmonary embolismClinical trialTreatment OutcomeHemostasisEmergency medicinePulmonary Embolismbusiness030215 immunologyHämostaseologie
researchProduct

Risk-adapted management of pulmonary embolism

2017

The presence and severity of right ventricular (RV) dysfunction is a key determinant of prognosis in the acute phase of pulmonary embolism (PE). Risk-adapted treatment strategies continue to evolve, tailoring initial management to the clinical presentation and the functional status of the RV. Beyond pharmacological and, if necessary, mechanical circulatory support, systemic thrombolysis remains the mainstay of treatment for hemodynamically unstable patients; in contrast, it is not routinely recommended for intermediate-risk PE. Catheter-directed pharmacomechanical reperfusion treatment represents a promising option for minimizing bleeding risk; for reduced-dose intravenous thrombolysis, the…

Riskmedicine.medical_specialtyVentricular Dysfunction Rightmedicine.medical_treatmentHemorrhage030204 cardiovascular system & hematologyDabigatran03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEdoxabanInternal medicinemedicineHumansThrombolytic Therapy030212 general & internal medicineIntensive care medicineRivaroxabanbusiness.industryAnticoagulantsDisease ManagementHematologyThrombolysisPrognosismedicine.diseasePulmonary embolismchemistryCirculatory systemCardiologyApixabanPulmonary EmbolismbusinessMajor bleedingmedicine.drugThrombosis Research
researchProduct

Neue orale Antikoagulanzien zur Therapie der venösen Thromboembolie

2011

In the current treatment of venous thromboembolism most patients are treated with vitamin K antagonists (VKA). VKA have many disadvantages including slow onset of action, multiple food and drug interactions and a large inter-individual variability in their efficacy. Recently several alternative oral anticoagulants have been developed, which have several advantages in comparison to VKA. So far two large randomized studies comparing new oral anticoagulants with VKA in patients with venous thromboembolism have been published: the RECOVER study with the oral direct thrombin antagonist dabigatran and the EINSTEIN-DVT study with the oral direct factor Xa-antagonist rivaroxaban. With regard to rec…

Rivaroxabanbusiness.industryGeneral MedicineVitamin kmedicine.diseaseDabigatranPulmonary embolismchemistry.chemical_compoundchemistryEdoxabanAnesthesiaMedicineApixabanOnset of actionbusinessVenous thromboembolismmedicine.drugDMW - Deutsche Medizinische Wochenschrift
researchProduct

Power of the Wilcoxon–Mann–Whitney test for non‐inferiority in the presence of death‐censored observations

2017

In clinical trials with patients in a critical state, death may preclude measurement of a quantitative endpoint of interest, and even early measurements, for example for intention-to-treat analysis, may not be available. For example, a non-negligible proportion of patients with acute pulmonary embolism will die before 30 day measurements on the efficacy of thrombolysis can be obtained. As excluding such patients may introduce bias, alternative analyses, and corresponding means for sample size calculation are needed. We specifically consider power analysis in a randomized clinical trial setting in which the goal is to demonstrate noninferiority of a new treatment as compared to a reference t…

Statistics and ProbabilityClinical Trials as TopicBiometryEndpoint Determinationbusiness.industryNonparametric statisticsGeneral Medicinemedicine.diseaseOutcome (probability)Pulmonary embolismlaw.inventionDeathClinical trialRandomized controlled trialSample size determinationlawCensoring (clinical trials)StatisticsMann–Whitney U testHumansMedicineStatistics Probability and UncertaintyPulmonary EmbolismbusinessBiometrical Journal
researchProduct

Results of isolated posterolateral corner reconstruction

2010

Abstract Background Isolated posterolateral corner (PLC) tears are relatively rare events. Various surgical techniques to treat posterolateral knee instability have been described; because surgical results are linked to cruciate reconstructions it has been difficult to date to define whether one surgical procedure has better prognosis than another. The goal of this study is to determine the clinical outcome of PLC reconstruction following fibular-based technique. Materials and methods We retrospectively evaluated a case series of patients who received isolated PLC reconstruction between March 2005 and January 2007. Ten patients were surgically treated for isolated injuries and were availabl…

Surgical resultsMaleKnee JointPosterolateral corner (PLC) reconstructionKnee JointTendonsPostoperative ComplicationsSettore MED/33 - Malattie Apparato LocomotoreOrthopedics and Sports MedicineOrthopedic ProceduresRange of Motion ArticularVenous ThrombosisFibular collateral ligamentPosterolateral corner (PLC) reconstruction Fibular collateral ligament Knee ligament reconstruction Popliteofibular ligamentMiddle Agedmusculoskeletal systemTreatment OutcomePopliteofibular ligamentLigaments ArticularOriginal ArticleFemaleRadiologyRange of motionOrthopedic Proceduresmusculoskeletal diseasesAdultJoint InstabilityReoperationmedicine.medical_specialtyAdolescentKnee InjuriesTransplantation AutologousYoung AdultmedicinePosterolateral cornerHumansFibular collateral ligamentRetrospective StudiesArthritis Infectiousbusiness.industryKnee ligament reconstructionPlastic Surgery ProceduresSurgeryTransplantationOrthopedic surgeryChronic DiseaseSurgerybusinessPulmonary EmbolismFollow-Up Studies
researchProduct

Definition of tachycardia for risk stratification of pulmonary embolism

2020

Tachycardia is a reliable predictor of adverse outcomes in normotensive patients with acute pulmonary embolism (PE). However, different prognostic relevant heart rate thresholds have been proposed. The aim of the study was to investigate the prognostic performance of different thresholds used for defining tachycardia in normotensive PE patients.We performed a post-hoc analysis of normotensive patients with confirmed PE consecutively included in a single-centre and a multi-centre registry. An adverse outcome was defined as PE-related death, need for mechanical ventilation, cardiopulmonary resuscitation or administration of catecholamines.Of 1567 patients (median age: 72 [IQR, 59-79] years; f…

Tachycardiamedicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineTachycardiaInternal medicineHeart rateInternal MedicineHumansMedicineIn patient030212 general & internal medicineCardiopulmonary resuscitationAgedMechanical ventilationbusiness.industryGuidelineMiddle AgedPrognosismedicine.diseasePulmonary embolismROC CurveRisk stratificationCardiologyFemalemedicine.symptomPulmonary EmbolismbusinessEuropean Journal of Internal Medicine
researchProduct